OverviewChartNewsTraderScreen

Vaccinex/  US9186403013  /

IEX
11/15/2024  6:57:26 PM Chg. -0.19 Volume Bid- Ask- High Low
3.34USD -5.38% 300
Turnover: 1,079.37		 -Bid Size: - -Ask Size: - 3.73 3.34
GlobeNewswire 8/14 Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s ...
GlobeNewswire 7/31 Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease
GlobeNewswire 7/17 Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease a...
GlobeNewswire 6/6 Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepin...
GlobeNewswire 5/16 Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire 4/2 Vaccinex Reports 2023 Financial Results and Provides Corporate Update
GlobeNewswire 3/27 Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Pr...
GlobeNewswire 2/21 Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
GlobeNewswire 2/15 Vaccinex, Inc. Announces Reverse Stock Split
GlobeNewswire 2/7 Vaccinex Announces Pricing of $3.7 Million PIPE Financing
GlobeNewswire 1/3 US Neurologists Optimistic Regarding the Huntington’s Disease Treatment Pipeline, Emphasizing Haltin...
GlobeNewswire 12/4/2023 Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule
GlobeNewswire 11/13/2023 Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
GlobeNewswire 10/31/2023 Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combinat...
GlobeNewswire 10/26/2023 Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Ne...
GlobeNewswire 9/29/2023 Vaccinex Announces Pricing of $9.6 Million Public Offering
GlobeNewswire 9/28/2023 Vaccinex’s Next Generation ActivMAb® Technology Published in mAbs, a Leading Biotech Journal, and Va...
GlobeNewswire 9/27/2023 Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application
GlobeNewswire 9/26/2023 Vaccinex Reports Groundbreaking Findings at Medical Conferences Supporting Development of Pepinemab ...
GlobeNewswire 9/22/2023 Vaccinex, Inc. Announces Reverse Stock Split
GlobeNewswire 2/24/2022 Vaccinex, Inc. to Present at CHDI’s 17th Annual HD Therapeutics Conference Meeting
GlobeNewswire 1/27/2022 Vaccinex Announces $6.6 Million Private Placement
GlobeNewswire 1/26/2022 Vaccinex Reports Two Complete Responses in First Three Patients Enrolled in the Phase 1b/2 KEYNOTE-B...
GlobeNewswire 11/10/2021 Vaccinex, Inc. to Present at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
GlobeNewswire 11/9/2021 Vaccinex, Inc. to Present at the Clinical Trials on Alzheimer’s Disease (CTAD) Meeting